Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Profilate HT was provided on a named patient basis in the UK

  • Read more about Profilate HT was provided on a named patient basis in the UK

Over the years the text of the Profilate warning was amended to take account of changes to screening tests, but the final sentence remained unchanged.

  • Read more about Over the years the text of the Profilate warning was amended to take account of changes to screening tests, but the final sentence remained unchanged.

Profilate licensed with the following warning: "This product is prepared from units of human plasma which have been tested and found nonreactive for Hepatitis Associated Antigen. However, it is recognized that presently available methods are not sensitive enough to detect all units of potential infectious plasma and the risk of transmitting hepatitis is still present".

  • Read more about Profilate licensed with the following warning: "This product is prepared from units of human plasma which have been tested and found nonreactive for Hepatitis Associated Antigen. However, it is recognized that presently available methods are not sensitive enough to detect all units of potential infectious plasma and the risk of transmitting hepatitis is still present".

Profilate HT gained market share as a consequence of growing confidence that its technique of "wet heat treatment" reduced, although did not eliminate, the risk of infection with non-A non-B Hepatitis as well as inactivating HIV.

  • Read more about Profilate HT gained market share as a consequence of growing confidence that its technique of "wet heat treatment" reduced, although did not eliminate, the risk of infection with non-A non-B Hepatitis as well as inactivating HIV.

Survey of commercially-produced and NHS-produced Factor 8 concentrates refers to Hemofil, Kryobulin and Profilate as three main products licensed in the UK.

  • Read more about Survey of commercially-produced and NHS-produced Factor 8 concentrates refers to Hemofil, Kryobulin and Profilate as three main products licensed in the UK.

Sales figures for the year ending October 1976 showed that Hemofil and Kryobulin were the most used products, followed by Factorate and Profilate.

  • Read more about Sales figures for the year ending October 1976 showed that Hemofil and Kryobulin were the most used products, followed by Factorate and Profilate.

The levels of onward purchase by regional hospital boards both for Kryobulin and Hemofil were not as expected.

  • Read more about The levels of onward purchase by regional hospital boards both for Kryobulin and Hemofil were not as expected.

Kryobulin and Hemofil, the first products to be licensed for use in the UK, were the subject of a one year central contract for ten million international units between the UK companies importing them and the Department of Health and Social Services and Welsh Office

  • Read more about Kryobulin and Hemofil, the first products to be licensed for use in the UK, were the subject of a one year central contract for ten million international units between the UK companies importing them and the Department of Health and Social Services and Welsh Office

The UK was a marketplace for five main commercial Factor 8 products: Hemofil - manufactured by Hyland Therapeutics, Kryobulin - manufactured by Immuno AG, Profilate - manufactured by Abbott Laboratories and then by Alpha Therapeutic Corporation, Factorate - manufactured by the Armour Pharmaceutical Company, and Koate - manufactured by the Cutter Laboratories Inc.

  • Read more about The UK was a marketplace for five main commercial Factor 8 products: Hemofil - manufactured by Hyland Therapeutics, Kryobulin - manufactured by Immuno AG, Profilate - manufactured by Abbott Laboratories and then by Alpha Therapeutic Corporation, Factorate - manufactured by the Armour Pharmaceutical Company, and Koate - manufactured by the Cutter Laboratories Inc.

Cheaper imported plasma formed the basic material for concentrates distributed into 1977 and 1978.

  • Read more about Cheaper imported plasma formed the basic material for concentrates distributed into 1977 and 1978.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 315
  • Page 316
  • Page 317
  • Page 318
  • Current page 319
  • Page 320
  • Page 321
  • Page 322
  • Page 323
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.